Istari Oncology, Inc.

Istari Oncology, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies to treat various solid tumors, enhancing the body’s antitumor immune response. Founded in 2014, Istari Oncology, Inc. is based in Morrisville, US, and specializes in immunotherapy treatments.

The company has raised a total of USD 1. 1 mn, with its latest funding round occurring on February 1, 2021, led by Pappas Capital. The firm has been involved in three deals to date. Istari Oncology's core product is Lerapolturev, an innovative immunotherapy designed to enhance antitumor immunity by addressing the limitations of current immune checkpoint inhibitors.

Lerapolturev has been administered to over 200 patients and is currently undergoing multiple Phase 2 clinical trials targeting various solid tumors, including recurrent glioblastoma (rGBM) and advanced melanoma. This treatment reactivates existing anticancer T cells while addressing the immunosuppressive tumor microenvironment, offering a dual approach to cancer therapy. The company serves a broad client base that includes healthcare providers, hospitals, and cancer treatment centers, primarily in the United States, with plans to expand into European and Asian markets as clinical trials progress. Istari Oncology's revenue model is based on partnerships and collaborations with healthcare providers and research institutions involved in the clinical trials and commercialization of Lerapolturev.

The company utilizes a business-to-business (B2B) transaction structure, allowing hospitals and treatment centers to integrate Lerapolturev into their treatment protocols following regulatory approvals. Revenue is generated through direct sales of treatments and potentially through collaborative research agreements with pharmaceutical companies interested in developing combination therapies. The flagship product and its associated clinical trials strategically position the company to take advantage of the growing demand for advanced cancer therapies. Istari Oncology plans to further develop Lerapolturev and other potential therapies while expanding into new markets, specifically targeting Europe and Asia in the coming years.

The company intends to utilize the funds raised in February 2021 to support these initiatives and enhance its clinical trial operations, facilitating the introduction of innovative treatment options to a broader patient population.